AstraZeneca (LON:AZN) had its target price lifted by Berenberg Bank from GBX 5,800 ($81.32) to GBX 6,000 ($84.13) in a report released on Thursday morning. Berenberg Bank currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the subject of a number of other reports. UBS Group set a GBX 4,550 ($63.80) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Monday, October 23rd. Deutsche Bank restated a buy rating and set a GBX 5,600 ($78.52) price objective on shares of AstraZeneca in a research report on Wednesday, October 11th. JPMorgan Chase & Co. set a GBX 5,500 ($77.12) price objective on AstraZeneca and gave the stock a buy rating in a research report on Thursday, January 4th. Morgan Stanley restated an equal weight rating and set a GBX 5,000 ($70.11) price objective on shares of AstraZeneca in a research report on Friday, December 1st. Finally, Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Hold and a consensus target price of GBX 5,211.65 ($73.07).
Shares of AstraZeneca (AZN) traded down GBX 52 ($0.73) during midday trading on Thursday, reaching GBX 4,793 ($67.20). The company’s stock had a trading volume of 1,530,000 shares, compared to its average volume of 1,980,000. AstraZeneca has a 12-month low of GBX 4,260 ($59.73) and a 12-month high of GBX 5,520 ($77.40). The firm has a market cap of $60,560.00 and a price-to-earnings ratio of 2,819.41.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.